Jon P. Stonehouse - Dec 1, 2022 Form 4 Insider Report for BIOCRYST PHARMACEUTICALS INC (BCRX)

Role
President & CEO, Director
Signature
/s/ Alane P. Barnes, by power of attorney
Stock symbol
BCRX
Transactions as of
Dec 1, 2022
Transactions value $
-$3,429,364
Form type
4
Date filed
12/2/2022, 05:33 PM
Previous filing
Jan 4, 2023
Next filing
Dec 19, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BCRX Common Stock Options Exercise $305K +215K +23.83% $1.42* 1.12M Dec 1, 2022 Direct F1
transaction BCRX Common Stock Sale -$2.79M -215K -19.24% $13.00 902K Dec 1, 2022 Direct F1, F2
transaction BCRX Common Stock Options Exercise $117K +82.7K +9.17% $1.42* 984K Dec 2, 2022 Direct F1
transaction BCRX Common Stock Sale -$1.06M -82.7K -8.4% $12.80 902K Dec 2, 2022 Direct F1, F3
holding BCRX Common Stock 5K Dec 1, 2022 By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
holding BCRX Common Stock 5K Dec 1, 2022 By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -215K -72.22% $0.00 82.7K Dec 1, 2022 Common Stock 215K $1.42 Direct F1
transaction BCRX Emp. Stock Option (Right to Buy) Options Exercise $0 -82.7K -100% $0.00* 0 Dec 2, 2022 Common Stock 82.7K $1.42 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 10, 2021. The options were originally granted to the reporting person on January 1, 2013 and would have expired on January 1, 2023. The shares sold subsequent to the exercise of such options represent less than 10% of the reporting person's holdings of the issuer's securities.
F2 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.75 to $13.45. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.
F3 The price in column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $12.69 to $12.92. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote.